sb 202190 has been researched along with Diabetes Mellitus in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wenzel, S | 1 |
| Soltanpour, G | 1 |
| Schlüter, KD | 1 |
1 other study available for sb 202190 and Diabetes Mellitus
| Article | Year |
|---|---|
No correlation between the p38 MAPK pathway and the contractile dysfunction in diabetic cardiomyocytes: hyperglycaemia-induced signalling and contractile function.
Topics: Animals; Antioxidants; Ascorbic Acid; Cells, Cultured; Diabetes Mellitus; Electrophysiology; Glucose | 2005 |